Exploring Prognosis, Tumor Microenvironment and Tumor Immune Infiltration in Hepatocellular Carcinoma Based on ATF/CREB Transcription Factor Family Gene-Related Model

References

• Hai T, Hartman MG. The molecular biology and nomenclature of the activating transcription factor/cAMP responsive element binding family of transcription factors: activating transcription factor proteins and homeostasis. Gene. 2001;273(1):1–11. doi:10.1016/S0378-1119(01)00551-0
   PubMed Web of Science ®Google Scholar
• Cui A, Ding D, Li Y. Regulation of hepatic metabolism and cell growth by the ATF/CREB family of transcription factors. Diabetes. 2021;70(3):653–664. doi:10.2337/dbi20-0006
   PubMed Web of Science ®Google Scholar
• Lin HV, Accili D. Hormonal regulation of hepatic glucose production in health and disease. Cell Metab. 2011;14(1):9–19. doi:10.1016/j.cmet.2011.06.003
   PubMed Web of Science ®Google Scholar
• Lou MD, Li J, Cheng Y, et al. Glucagon up-regulates hepatic mitochondrial pyruvate carrier 1 through cAMP-responsive element-binding protein; inhibition of hepatic gluconeogenesis by ginsenoside Rb1. Br J Pharmacol. 2019;176(16):2962–2976. doi:10.1111/bph.14758
   PubMed Web of Science ®Google Scholar
• Allen-Jennings AE, Hartman MG, Kociba GJ, Hai T. The roles of ATF3 in glucose homeostasis. A transgenic mouse model with liver dysfunction and defects in endocrine pancreas. J Biol Chem. 2001;276(31):29507–29514. doi:10.1074/jbc.M100986200
   PubMed Web of Science ®Google Scholar
• Seo HY, Kim MK, Min AK, et al. Endoplasmic reticulum stress-induced activation of activating transcription factor 6 decreases cAMP-stimulated hepatic gluconeogenesis via inhibition of CREB. Endocrinology. 2010;151(2):561–568. doi:10.1210/en.2009-0641
   PubMed Web of Science ®Google Scholar
• Lee MW, Chanda D, Yang J, et al. Regulation of hepatic gluconeogenesis by an ER-bound transcription factor, CREBH. Cell Metab. 2010;11(4):331–339. doi:10.1016/j.cmet.2010.02.016
   PubMed Web of Science ®Google Scholar
• Tsai WW, Matsumura S, Liu W, et al. ATF3 mediates inhibitory effects of ethanol on hepatic gluconeogenesis. Proc Natl Acad Sci U S A. 2015;112(9):2699–2704. doi:10.1073/pnas.1424641112
   PubMed Web of Science ®Google Scholar
• Koo SH, Flechner L, Qi L, et al. The CREB coactivator TORC2 is a key regulator of fasting glucose metabolism. Nature. 2005;437(7062):1109–1111. doi:10.1038/nature03967
   PubMed Web of Science ®Google Scholar
• Kim H, Zheng Z, Walker PD, Kapatos G, Zhang K. CREBH maintains circadian glucose homeostasis by regulating hepatic glycogenolysis and gluconeogenesis. Mol Cell Biol. 2017;37(14). doi:10.1128/MCB.00048-17
   Web of Science ®Google Scholar
• Shuda M, Kondoh N, Imazeki N, et al. Activation of the ATF6, XBP1 and grp78 genes in human hepatocellular carcinoma: a possible involvement of the ER stress pathway in hepatocarcinogenesis. J Hepatol. 2003;38(5):605–614. doi:10.1016/S0168-8278(03)00029-1
   PubMed Web of Science ®Google Scholar
• Chin KT, Zhou HJ, Wong CM, et al. The liver-enriched transcription factor CREB-H is a growth suppressor protein underexpressed in hepatocellular carcinoma. Nucleic Acids Res. 2005;33(6):1859–1873. doi:10.1093/nar/gki332
   PubMed Web of Science ®Google Scholar
• Chen C, Ge C, Liu Z, et al. ATF3 inhibits the tumorigenesis and progression of hepatocellular carcinoma cells via upregulation of CYR61 expression. J Exp Clin Cancer Res. 2018;37(1):263. doi:10.1186/s13046-018-0919-8
   PubMedGoogle Scholar
• Wu Y, Wu B, Chen R, Zheng Y, Huang Z. High ATF5 expression is a favorable prognostic indicator in patients with hepatocellular carcinoma after hepatectomy. Med Oncol. 2014;31(11):269. doi:10.1007/s12032-014-0269-0
   PubMed Web of Science ®Google Scholar
• Llovet JM, Kelley RK, Villanueva A, et al.Hepatocellular carcinoma. Nat Rev Dis Primers. 2021;7(1):7. doi:10.1038/s41572-021-00245-6
   PubMed Web of Science ®Google Scholar
• Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209–249. doi:10.3322/caac.21660
   PubMed Web of Science ®Google Scholar
• Llovet JM, Zucman-Rossi J, Pikarsky E, et al. Hepatocellular carcinoma. Nat Rev Dis Primers. 2016;2:16018. doi:10.1038/nrdp.2016.18
   PubMed Web of Science ®Google Scholar
• Wilson GC, Geller DA. Evolving Surgical Options for Hepatocellular Carcinoma. Surg Oncol Clin N Am. 2019;28(4):645–661. doi:10.1016/j.soc.2019.06.006
   PubMed Web of Science ®Google Scholar
• Serper M, Taddei TH, Mehta R, et al. Association of provider specialty and multidisciplinary care with hepatocellular carcinoma treatment and mortality. Gastroenterology. 2017;152(8):1954–1964. doi:10.1053/j.gastro.2017.02.040
   PubMed Web of Science ®Google Scholar
• Huang A, Yang XR, Chung WY, Dennison AR, Zhou J. Targeted therapy for hepatocellular carcinoma. Signal Transduct Target Ther. 2020;5(1):146. doi:10.1038/s41392-020-00264-x
   PubMed Web of Science ®Google Scholar
• Sangro B, Sarobe P, Hervas-Stubbs S, Melero I. Advances in immunotherapy for hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol. 2021;18(8):525–543. doi:10.1038/s41575-021-00438-0
   PubMed Web of Science ®Google Scholar
• Colaprico A, Silva TC, Olsen C, et al. TCGAbiolinks: an R/Bioconductor package for integrative analysis of TCGA data. Nucleic Acids Res. 2016;44(8):e71. doi:10.1093/nar/gkv1507
   PubMed Web of Science ®Google Scholar
• Chen B, Khodadoust MS, Liu CL, Newman AM, Alizadeh AA. Profiling tumor infiltrating immune cells with CIBERSORT. Methods Mol Biol. 2018;1711:243–259.
   PubMedGoogle Scholar
• Han HS, Kang G, Kim JS, Choi BH, Koo SH. Regulation of glucose metabolism from a liver-centric perspective. Exp Mol Med. 2016;48:e218. doi:10.1038/emm.2015.122
   PubMed Web of Science ®Google Scholar
• Jones JG. Hepatic glucose and lipid metabolism. Diabetologia. 2016;59(6):1098–1103. doi:10.1007/s00125-016-3940-5
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR, Roden M. NAFLD and diabetes mellitus. Nat Rev Gastroenterol Hepatol. 2017;14(1):32–42. doi:10.1038/nrgastro.2016.147
   PubMed Web of Science ®Google Scholar
• Arai M, Kondoh N, Imazeki N, et al. Transformation-associated gene regulation by ATF6alpha during hepatocarcinogenesis. FEBS Lett. 2006;580(1):184–190. doi:10.1016/j.febslet.2005.11.072
   PubMed Web of Science ®Google Scholar
• Yang JD, Heimbach JK. New advances in the diagnosis and management of hepatocellular carcinoma. BMJ. 2020;371:m3544. doi:10.1136/bmj.m3544
   PubMed Web of Science ®Google Scholar
• Leone P, Solimando AG, Fasano R, et al. The evolving role of immune checkpoint inhibitors in hepatocellular carcinoma treatment. Vaccines. 2021;9(5). doi:10.3390/vaccines9050532
   Web of Science ®Google Scholar
• Cai W, Liu Z, Xiao Y, et al. Comparison of clinical outcomes of laparoscopic versus open surgery for recurrent hepatocellular carcinoma: a meta-analysis. Surg Endosc. 2019;33(11):3550–3557. doi:10.1007/s00464-019-06996-4
   PubMed Web of Science ®Google Scholar
• Vivarelli M, Cucchetti A, La Barba G, et al. Liver transplantation for hepatocellular carcinoma under calcineurin inhibitors: reassessment of risk factors for tumor recurrence. Ann Surg. 2008;248(5):857–862. doi:10.1097/SLA.0b013e3181896278
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver. Electronic address eee, European Association for the Study of the L. EASL clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol. 2018;69(1):182–236. doi:10.1016/j.jhep.2018.03.019
   PubMed Web of Science ®Google Scholar
• Beleù A, Autelitano D, Geraci L, et al. Radiofrequency ablation of hepatocellular carcinoma: CT texture analysis of the ablated area to predict local recurrence. Eur J Radiol. 2022;150:110250. doi: 10.1016/j.ejrad.2022.110250
   PubMed Web of Science ®Google Scholar
• Ikeda M, Morizane C, Ueno M, Okusaka T, Ishii H, Furuse J. Chemotherapy for hepatocellular carcinoma: current status and future perspectives. Jpn J Clin Oncol. 2018;48(2):103–114. doi:10.1093/jjco/hyx180
   PubMed Web of Science ®Google Scholar
• Yamamoto S, Kondo S. Oral chemotherapy for the treatment of hepatocellular carcinoma. Expert Opin Pharmacother. 2018;19(9):993–1001. doi:10.1080/14656566.2018.1479398
   PubMed Web of Science ®Google Scholar
• Kirstein MM, Wirth TC. Multimodale Therapie des hepatozellulären Karzinoms[Multimodal treatment of hepatocellular carcinoma]. Internist. 2020;61(2):164–169. German. doi:10.1007/s00108-019-00722-x
   PubMedGoogle Scholar
• Johnston MP, Khakoo SI. Immunotherapy for hepatocellular carcinoma: current and future. World J Gastroenterol. 2019;25(24):2977–2989. doi:10.3748/wjg.v25.i24.2977
   PubMed Web of Science ®Google Scholar
• Solimando AG, Susca N, Argentiero A, et al. Second-line treatments for advanced hepatocellular carcinoma: a systematic review and bayesian network meta-analysis. Clin Exp Med. 2022;22(1):65–74. doi:10.1007/s10238-021-00727-7
   PubMed Web of Science ®Google Scholar
• Liew PX, Kubes P. The neutrophil’s role during health and disease. Physiol Rev. 2019;99(2):1223–1248. doi:10.1152/physrev.00012.2018
   PubMed Web of Science ®Google Scholar
• Ding G, Li W, Liu J, et al. LncRNA GHET1 activated by H3K27 acetylation promotes cell tumorigenesis through regulating ATF1 in hepatocellular carcinoma. Biomed Pharmacother. 2017;94:326–331. doi:10.1016/j.biopha.2017.07.046
   PubMed Web of Science ®Google Scholar
• Li Y, Fu Y, Hu X, et al. The HBx-CTTN interaction promotes cell proliferation and migration of hepatocellular carcinoma via CREB1. Cell Death Dis. 2019;10(6):405. doi:10.1038/s41419-019-1650-x
   PubMed Web of Science ®Google Scholar
• Hossain MA, Liu G, Dai B, et al. Reinvigorating exhausted CD8(+) cytotoxic T lymphocytes in the tumor microenvironment and current strategies in cancer immunotherapy. Med Res Rev. 2021;41(1):156–201. doi:10.1002/med.21727
   PubMed Web of Science ®Google Scholar
• Lees JR. CD8+ T cells: the past and future of immune regulation. Cell Immunol. 2020;357:104212. doi:10.1016/j.cellimm.2020.104212
   PubMed Web of Science ®Google Scholar
• Brossart P, Wirths S, Brugger W, Kanz L. Dendritic cells in cancer vaccines. Exp Hematol. 2001;29(11):1247–1255. doi:10.1016/S0301-472X(01)00730-5
   PubMed Web of Science ®Google Scholar
• Zeng Z, Gao Y, Li J, et al. Violations of proportional hazard assumption in Cox regression model of transcriptomic data in TCGA pan-cancer cohorts. Comput Struct Biotechnol J. 2022;20:496–507. doi:10.1016/j.csbj.2022.01.004
   PubMed Web of Science ®Google Scholar
• Park SH, Goo JM, Jo CH. Receiver operating characteristic (ROC) curve: practical review for radiologists. Korean J Radiol. 2004;5(1):11–18. doi:10.3348/kjr.2004.5.1.11
   PubMed Web of Science ®Google Scholar
• Obuchowski NA, Bullen JA. Receiver operating characteristic (ROC) curves: review of methods with applications in diagnostic medicine. Phys Med Biol. 2018;63(7):07TR01. doi:10.1088/1361-6560/aab4b1
   PubMed Web of Science ®Google Scholar
• Kamarudin AN, Cox T, Kolamunnage-Dona R. Time-dependent ROC curve analysis in medical research: current methods and applications. BMC Med Res Methodol. 2017;17(1):53. doi:10.1186/s12874-017-0332-6
   PubMed Web of Science ®Google Scholar